Ten years ago, the U.S. Supreme Court issued its 5-3 decision in FTC v. Actavis, […]
There is a growing interest in understanding the “ownership interests hypothesis,” i.e., whether investors holding […]
Generics and biosimilars are an important part of the pharmaceutical landscape in Europe. What are […]
Although there is little question as to the need for affordable, accessible, and high-quality pharmaceuticals, […]